The impact of (68)gallium DOTA PET/CT in managing patients with sporadic and familial pancreatic neuroendocrine tumours
Authors
Cuthbertson, D. J.Barriuso, Jorge
Lamarca, Angela
Manoharan, Prakash
Westwood, T.
Jaffa, M.
Fenwick, S. W.
Nuttall, C.
Lalloo, F.
Prachalias, A.
Pizanias, M.
Wieshmann, H.
McNamara, Mairead G
Hubner, Richard A
Srirajaskanthan, R.
Vivian, G.
Ramage, J.
Weickert, M. O.
Pritchard, D. M.
Vinjamuri, S.
Valle, Juan W
Yip, V. S.
Affiliation
Liverpool University Hospitals NHS Foundation Trust, ENETS Centre of Excellence, Liverpool, United Kingdom.Issue Date
2021
Metadata
Show full item recordAbstract
Objective: Pancreatic neuroendocrine tumours (panNETs) arise sporadically or as part of a genetic predisposition syndrome. CT/MRI, endoscopic ultrasonography and functional imaging using Octreoscan localise and stage disease. This study aimed to evaluate the complementary role of 68Gallium (68Ga)-DOTA PET/CT in managing patients with panNETs. Design: A retrospective study conducted across three tertiary UK NET referral centres. Methods: Demographic, clinical, biochemical, cross-sectional and functional imaging data were collected from patients who had undergone a 68Ga-DOTA PET/CT scan for a suspected panNET. Results: We collected data for 183 patients (97 male): median (SD) age 63 (14.9) years, 89.1 vs. 9.3% (n=163 vs. 17) alive vs. dead (3 data missing), 141 sporadic vs. 42 familial (MEN1, n=36; 85.7%) panNETs. Non-functional vs. functional tumours comprised 73.2 vs. 21.3% (n=134 vs. 39) (10 missing). Histological confirmation was available in 89% of individuals (n=163) but tumour grading (Ki67 classiifcation) was technically possible only in a smaller cohort (n=143): grade 1, 50.3% (n=72); grade 2, 46.2% (n=66) and grade 3, 3.5% (n=5) (40 histopathological classification either not technically feasible or biopsy not perfomed). 60.1% (n=110) were localised, 14.2% (n=26) locally advanced and 23.5% (n=43) metastatic (4 missing). 224 68Ga-DOTA PET/CT scans were performed in total for: diagnosis/staging 40% (n=88), post-operative assessment/clinical surveillance 53% (n=117) and consideration of peptide receptor radionuclide therapy (PRRT) 8% (n=17) (2 missing). PET/CT results confirmed other imaging findings (53%), identified new disease sites (28.5%) and excluded suspected disease (5%). Overall, 68Ga-DOTA PET/CT imaging findings provided additional information in 119 (54%) patients and influenced management in 85 (39%) cases. Conclusion: 68Ga-DOTA PET/CT imaging more accurately stages and guides treatment in patients with sporadic/familial panNETs with newly diagnosed/recurrent disease.Citation
Cuthbertson DJ, Barriuso J, Lamarca A, Manoharan P, Westwood T, Jaffa M, et al. The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. Front Endocrinol . 2021 Jun 7;12.Journal
Frontiers in EndocrinologyDOI
10.3389/fendo.2021.654975PubMed ID
34163434Additional Links
https://dx.doi.org/10.3389/fendo.2021.654975Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.3389/fendo.2021.654975
Scopus Count
Collections
Related articles
- Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
- Authors: Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ
- Issue date: 2013 Feb
- Added value of [(68)Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort.
- Authors: Yoo J, Kim SH, Jeon SK, Bae JS, Han JK
- Issue date: 2021 Oct
- (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.
- Authors: Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S
- Issue date: 2010 Apr
- Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
- Authors: Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M
- Issue date: 2016 Aug
- Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.
- Authors: Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, Grassetto G, Rubello D, Nanni C, Franchi R
- Issue date: 2008 Dec